DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
AZD-5423 is an investigational drug.
There have been 30 clinical trials for AZD-5423. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Small Cell Lung Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
Recent Clinical Trials for AZD-5423
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Phase 2|
|Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||M.D. Anderson Cancer Center||Phase 2|
|Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer||AstraZeneca||Phase 2|